KROS

#3546
Keros Therapeutics, Inc. - common stock
11.0 7 USD
0.00%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
11.07
11.07
Jahresspanne
9.69
22.55
Tagesänderung
-0.09%
Monatliche Änderung
+8.96%
6 month change
-19.78%
Jahresänderung
-26.69%
Vorheriger Schlusskurs
11.0 8
Open
11.0 7
Tief
11.0 7
Hoch
11.0 7
Volumen
25
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Keros Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Keros Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Keros Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Keros Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Keros Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Keros Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Keros Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Keros Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Keros Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Keros Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q

Keros Therapeutics, Inc. current report, Q3 FY2026

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Keros Therapeutics, Inc. on July 17, 2026. The filing discloses an executive transition involving the resignation of the Chief Financial Officer and the appointment of an interim successor.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on personnel changes and associated compensation arrangements.

Material Changes

  • Departure of CFO: Keith Regnante resigned as Chief Financial Officer, effective August 3, 2026. The resignation was voluntary and not related to any disagreement regarding accounting practices or financial reporting.
  • Interim Appointment: Annita Tanini, previously Corporate Controller and Vice President of Finance, was appointed as interim Principal Financial Officer and Principal Accounting Officer, effective August 4, 2026.
  • Search for Permanent CFO: The Company has commenced a search for a permanent Chief Financial Officer.

Compensation, Outlook, and Risks

Compensation Arrangements

  • Annita Tanini (Interim CFO):
    • Annual base salary: $302,300.
    • Target annual cash bonus: 30% of base salary.
    • Severance (without cause/good reason): Six months of base salary and COBRA premiums for up to six months, subject to a general release of claims.
  • Keith Regnante (Outgoing CFO):
    • Entitled to accrued base salary through the separation date.
    • Reimbursement of unreimbursed business expenses.
    • COBRA continuation coverage at his sole expense.
    • No additional severance payments or compensation beyond accrued amounts and legal requirements.

Outlook and Risks

The filing does not contain updated financial guidance or specific risk factors beyond the standard disclosure that the executive transition is voluntary and unrelated to financial reporting disputes. The Company is currently operating with an interim CFO while searching for a permanent replacement.

Investor Verification Checklist

  • Verify the effective dates of the CFO transition (August 3, 2026, for resignation; August 4, 2026, for appointment).
  • Review the upcoming Form 10-Q for the quarter ending June 30, 2026, for the full text of the Tanini Employment Agreement.
  • Monitor future filings for the appointment of a permanent Chief Financial Officer.
  • Confirm that no undisclosed disagreements exist regarding financial reporting, as explicitly stated in the filing.

Nachrichten